Simmons Bank raised its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 1.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,409 shares of the company’s stock after purchasing an additional 121 shares during the period. Simmons Bank’s holdings in Eli Lilly and Company were worth $7,450,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of LLY. Haverford Trust Co raised its holdings in Eli Lilly and Company by 0.9% in the 3rd quarter. Haverford Trust Co now owns 3,515 shares of the company’s stock worth $3,114,000 after acquiring an additional 31 shares during the period. Empower Advisory Group LLC increased its stake in shares of Eli Lilly and Company by 4.3% in the third quarter. Empower Advisory Group LLC now owns 139,274 shares of the company’s stock worth $123,388,000 after purchasing an additional 5,682 shares during the period. Moser Wealth Advisors LLC lifted its position in shares of Eli Lilly and Company by 40.0% during the 3rd quarter. Moser Wealth Advisors LLC now owns 455 shares of the company’s stock worth $403,000 after purchasing an additional 130 shares during the last quarter. Carrera Capital Advisors bought a new stake in Eli Lilly and Company during the 3rd quarter valued at approximately $244,000. Finally, Victory Capital Management Inc. grew its holdings in Eli Lilly and Company by 0.3% in the 3rd quarter. Victory Capital Management Inc. now owns 697,335 shares of the company’s stock valued at $617,797,000 after buying an additional 1,961 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on the company. Citigroup increased their price objective on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Berenberg Bank lifted their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Finally, Wells Fargo & Company upped their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Four analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $1,008.41.
Insider Buying and Selling at Eli Lilly and Company
In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.13% of the company’s stock.
Eli Lilly and Company Trading Down 1.6 %
Shares of LLY opened at $818.79 on Wednesday. The stock has a fifty day moving average price of $891.02 and a two-hundred day moving average price of $870.71. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The company has a market cap of $777.29 billion, a price-to-earnings ratio of 88.52, a PEG ratio of 3.15 and a beta of 0.43. Eli Lilly and Company has a 52-week low of $561.65 and a 52-week high of $972.53.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. During the same period in the prior year, the company earned $0.10 EPS. The firm’s revenue was up 20.4% compared to the same quarter last year. Analysts predict that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.64%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is 56.22%.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- Trading Stocks: RSI and Why it’s Useful
- Is Confluent the Next Big Winner in AI-Powered Data Streaming?
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Under-the-Radar AI Stock Vertiv Up 160% and Climbing
- Following Congress Stock Trades
- Is MARA a Safe Way to Get Exposure to the Bitcoin Rally?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.